Penn Medicine contributed to a $12m extension for the cancer immunotherapy developer's series B round, which already inlcuded Livzon, Merck & Co and AbbVie.

US-based cancer immunotherapy developer Carisma Therapeutics increased a series B round featuring Penn Medicine, which includes medical care provider University of Pennsylvania Health System, to $59m yesterday. Penn Medicine, commercialisation firm IP Group and venture capital firm 4Bio Capital added $12m to the $47m the company raised in a tranche in January this year that…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.